Lomardexamfetamine

Lomardexamfetamine
Clinical data
Other namesKP106; L-Homoarginine-D-amphetamine
Routes of
administration		Oral[1]
Drug classNorepinephrine–dopamine releasing agent; Stimulant
ATC code
  • None
Identifiers
  • (2S)-2-amino-6-(diaminomethylideneamino)-N-[(2S)-1-phenylpropan-2-yl]hexanamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC16H27N5O
Molar mass305.426 g·mol−1
3D model (JSmol)
  • C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN=C(N)N)N
  • InChI=1S/C16H27N5O/c1-12(11-13-7-3-2-4-8-13)21-15(22)14(17)9-5-6-10-20-16(18)19/h2-4,7-8,12,14H,5-6,9-11,17H2,1H3,(H,21,22)(H4,18,19,20)/t12-,14-/m0/s1
  • Key:DRLPEFJOKVYESM-JSGCOSHPSA-N

Lomardexamfetamine (INNTooltip International Nonproprietary Name; developmental code name KP-106), also known as L-homoarginine-D-amphetamine, is a psychostimulant of the amphetamine family which was under development for the treatment of attention deficit hyperactivity disorder (ADHD) but was never marketed.[1][2][3] It is taken orally as an oral film.[1] The drug is a prodrug of dextroamphetamine analogously to lisdexamfetamine and with similarly reduced misuse potential.[3][4] Lomardexamfetamine was originated and under development by KemPharm (now known as Zevra Therapeutics).[1][2][3] It reached phase 1 clinical trials prior to the discontinuation of its development in 2013.[1][2][3]

See also

References

  1. 1 2 3 4 5 "KP 106". AdisInsight. 26 February 2023. Retrieved 26 April 2026.
  2. 1 2 3 "Delving into the Latest Updates on Lomardexamfetamine with Synapse". Synapse. 25 April 2026. Retrieved 26 April 2026.
  3. 1 2 3 4 Rosenmayr-Templeton L (2011). "Industry Update: the Latest Developments in Therapeutic Delivery". Therapeutic Delivery. 2 (7): 853–859. doi:10.4155/tde.11.70. ISSN 2041-5990.
  4. ↑ Weisler RH, Childress AC (2011). "Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications". The Primary Care Companion for CNS Disorders. 13 (6). doi:10.4088/PCC.11r01168. PMC 3304687. PMID 22454805. In contrast to extended-release stimulants, which often contain immediate-release stimulant components that are susceptible to mechanical manipulation such as crushing, conversion of the lisdexamfetamine dimesylate prodrug to its active component requires conversion in the blood, potentially reducing abuse or diversion.65 While likeability for lisdexamfetamine dimesylate is lower and dosages needed to get an equivalent effect for drug abusers are higher, clinicians still must consider the potential for abuse of stimulant medications. Another amphetamine prodrug formulation in development, KP106, demonstrated a similar decreased abuse liability profile on the basis of preclinical studies.66
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.